# MM014

Source: https://onco.cc/drugs/mm014/  
OnCo record `mm014` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MM014 is an in vivo CAR-T programme from Mucommune for solid tumours, in early laboratory development.

## Summary

MM014 is listed on the pipeline page of Mucommune as an in vivo CAR-T programme for solid tumours, under its in vivo cell engineering platform. The company does not state the target or the stage on that page, and no clinical trial is registered.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Tags: pipeline
- Code: MM014
- Modality: In vivo CAR-T cell therapy
- Mechanism: Described by the company as in vivo CAR-T for solid tumours: the patient's T cells are engineered inside the body rather than in a manufacturing facility.

## Sources

- Mucommune pipeline: https://www.mucommune.com/pipeline

## Connected records

- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- companies: [Mucommune](https://onco.cc/companies/mucommune/)

---
JSON: https://onco.cc/api/v1/entities/mm014.json